Valion Bio, Shear Kershman Labs partner to develop oral mucosal Entolimod formulation

PUBT · 1d ago
Valion Bio, Shear Kershman Labs partner to develop oral mucosal Entolimod formulation
  • Valion Bio entered a collaboration with Shear Kershman Laboratories to develop an oral mucosal formulation of Entolimod using BioViscid.
  • Formulation work was completed, creating a needle-free delivery pathway alongside Valion’s injectable Entolimod program for radiation exposure.
  • Next study will assess whether oral mucosal dosing produces measurable systemic Entolimod exposure, informing pharmacokinetics and further development.
  • Valion estimates a successful needle-free product could expand potential US dosing needs by roughly 10 to 40 times versus injectable deployment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.